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Objective To estimate the association between lipoprotein particle
concentrations in pregnancy and gestational age at delivery.
Design Prospective cohort study.
Setting The study was conducted in the USA at the University of
North Carolina.
Population We assessed 715 women enrolled in the Pregnancy,
Infection, and Nutrition study from 2001 to 2005.
Methods Fasting blood was collected at two time points (<20 and
24–29 weeks of gestation). Nuclear magnetic resonance (NMR)
quantified lipoprotein particle concentrations [low-density
lipoprotein (LDL), high-density lipoprotein (HDL), very-low
density lipoprotein (VLDL)] and 10 subclasses of lipoproteins.
Concentrations were assessed as continuous measures, with the
exception of medium HDL which was classified as any or no
detectable level, given its distribution. Cox proportional hazards
models estimated hazard ratios (HR) for gestational age at
delivery adjusting for covariates.
Main outcome measures Gestational age at delivery, preterm birth
(<37 weeks of gestation), and spontaneous preterm birth.
Results At <20 weeks of gestation, three lipoproteins were
associated with later gestational ages at delivery [large LDLNMR
(HR 0.78, 95% CI 0.64–0.96), total VLDLNMR (HR 0.77, 95% CI
0.61–0.98), and small VLDLNMR (HR 0.78, 95% CI 0.62–0.98],
whereas large VLDLNMR (HR 1.19, 95% CI 1.01–1.41) was
associated with a greater hazard of earlier delivery. At 24–28 weeks
of gestation, average VLDLNMR (HR 1.25, 95% CI 1.03–1.51) and
a detectable level of medium HDLNMR (HR 1.90, 95% CI 1.19–
3.02) were associated with earlier gestational ages at delivery.
Conclusion In this sample of pregnant women, particle concentrations
of VLDLNMR, LDLNMR, IDLNMR, and HDLNMR were each
independently associated with gestational age at delivery for all
deliveries or spontaneous deliveries <37 weeks of gestation. These
findings may help formulate hypotheses for future studies of the
complex relationship between maternal lipoproteins and preterm birth.
Keywords Cholesterol, dyslipidaemia, gestational age at delivery,
lipoproteins, nuclear magnetic resonance spectroscopy, preterm
birth.
Tweetable abstract Nuclear magnetic resonance spectroscopy may
identify lipoprotein particles associated with preterm delivery.
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Introduction
Maternal metabolic changes in pregnancy increase fat stor-
age and subsequent mobilization of these stores to support
the growing fetus. In the second trimester, increasing estro-
gen, insulin, and insulin resistance increases maternal
serum fatty acids and lipoproteins. The relationship
between aberrations in lipid metabolism and adverse
cardiovascular and metabolic outcomes in adults is well
described. In pregnant women, exaggerations in lipopro-
teins are associated with adverse pregnancy outcomes such
as pre-eclampsia and gestational diabetes.1,2 These preg-
nancy complications are known risk factors for future
metabolic diseases.3,4 Maternal dysmetabolic conditions
may also enhance cardiovascular disease susceptibility in
offspring.5,6
Preterm birth is the leading cause of morbidity and mor-
tality among neonates without congenital anomalies in the
USA.7,8 Epidemiologic studies have demonstrated complex
associations between maternal metabolic disease, preterm
birth, and maternal risk of cardiovascular complications
later in life.9–16 The mechanism linking metabolic expo-
sures, pregnancy complications, and subsequent cardiovas-
cular outcomes is not well understood, however. Previous
studies associating maternal dyslipidaemia with preterm
birth risk vary by timing of sample collection, whether or
not the patient was fasting, lipids measured, and the tech-
nique used to measure lipid concentrations. They also rely
on traditional chemical techniques for measuring lipid con-
centrations that measure the cholesterol content of a per-
son’s low-density (LDL-C) and high-density (HDL-C)
lipoprotein particles, but not the absolute number of
lipoprotein particles. Previous studies have thus associated
lipid concentrations and not lipoprotein particle concentra-
tions with pregnancy outcomes.
Nuclear magnetic resonance (NMR) spectroscopy is an
alternative method of measuring lipoproteins that relies on
the characteristic NMR signals of lipoprotein particles to
quantify particle size and concentration.17 This is clinically
relevant because chemically measured lipoprotein lipid
levels and NMR-measured lipoprotein particle numbers are
not comparable. Two patients with the same lipid concen-
tration may have vastly different concentrations of particles
in their serum, and thus different risk profiles.18 Studies in
non-pregnant patients have demonstrated that lipid particle
concentrations measured by NMR have significant and
independent associations with cardiovascular disease events,
regardless of lipid concentrations.19–21 NMR has been used
in hundreds of studies in non-pregnant populations and
has yielded new insights into the roles of particle subtypes
in health outcomes. To date, only one study has reported
the use of NMR to associate maternal dyslipidaemia with
preterm bith; however, this study was limited by the fact
that it was a case–control study of women with a history of
preterm birth, used samples from non-fasting patients, and
had a different primary outcome.22 In addition, the investi-
gators only had one sample for each patient and were not
able to assess changes in lipids at two time points in preg-
nancy. The objective of our study was to use NMR to
determine whether lipoprotein particle concentrations at
two points in pregnancy were associated with gestational
age at delivery, specifically preterm birth and spontaneous
preterm birth, in a cohort of pregnant women.
Methods
Study population
The Pregnancy, Infection, and Nutrition Study (PIN) was a
large, multiphase, cohort study, the primary aim of which
was to identify aetiologic factors for preterm delivery. The
third phase of the study (PIN3) recruited women from pre-
natal clinics at the University of North Carolina before
20 weeks of gestation from 2001 to 2005 (n = 2006).
Women attended two research clinic visits (at <20 and 24–
29 weeks of gestation), providing a fasting blood sample at
each visit, completed two telephone interviews (at 17–22
and 27–30 weeks of gestation), and self-administered ques-
tionnaires at each clinic visit. Medical charts were
abstracted following delivery. Women were excluded from
participating in PIN3 if they were non-English speaking,
<16 years of age, carrying multiple gestations, not planning
to continue care or deliver at the study hospital, or did not
have a telephone for completing the interviews. The study
protocols were approved by the Institutional Review Board
at the University of North Carolina at Chapel Hill.
Of those eligible, 967 (63%) women agreed to participate
in the two research clinic visits and provide fasting blood
samples, and 755 (78.1%) consented to and had at least
one blood sample drawn. We further excluded women
missing data on gestational age at delivery (n = 3) and
those with a history of diabetes (n = 37). The final sample
included 715 women who provided at least one blood sam-
ple for analysis: 662 (92.6%) had two blood samples and
53 (7.4%) had one blood sample drawn during pregnancy.
Age, race, Hispanic ethnicity, education, and income
were reported during the first telephone interview; the
average number of cigarettes smoked in the first 6 months
of pregnancy was reported during the second phone inter-
view. Pre-pregnancy body mass index (BMI) was calculated
from self-reported weight and measured height, and was
categorised according to the recommendations of the Insti-
tute of Medicine (2009).23 Gestational age was determined
using both early ultrasound and last menstrual period. In
the PIN study, 96% of participants had an ultrasound per-
formed <22 weeks of gestation that was used to confirm
the gestational age. Spontaneous preterm birth was based
on clinical determination.
Lipoprotein particle analysis
Lipoproteins were measured by NMR Lipoprofile-II auto-
analyser (formerly of Liposcience, Inc., Raleigh, NC, USA;
now Laboratory Corporation of America, Burlington, NC,
USA). This technology allowed for the assessment of each
participant’s lipoprotein subclass particle size (in
nanometres) and concentration (particle nanomoles/l or
lmol/l), and included total LDLNMR, HDLNMR, and
VLDLNMR, and subclasses by particle size. It also provided
calculated values for mean VLDLNMR, LDLNMR, and
HDLNMR particle size, as well as total triglyceride levels.
The laboratory determined the thresholds for particle size
that were used to categorise the lipoprotein particle size
and concentration measurements from each plasma sample
into 16 subclasses, yielding up to 32 total assessments per
participant.
Lipoprotein particle concentrations and sizes were
assessed as continuous variables. Most women (70%) had
no detectable medium HDLNMR concentration at either
time point and, as such, medium HDLNMR was categorised
as any or no detectable concentration.
Statistical analysis
Descriptive analyses were conducted to compare maternal
and infant characteristics by preterm birth status. The asso-
ciations between gestational age at delivery and lipoprotein
particle concentrations, scaled to one standard deviation
(1 SD), were assessed using adjusted and unadjusted Cox
proportional hazard models, with gestational age as the
time scale. Time-varying coefficients were employed to esti-
mate separate hazard ratios (HRs) and 95% confidence
intervals (95% CIs) during the time period before and after
37 weeks of gestation, with HRs of delivery before
37 weeks of gestation being the target of inference. Adjust-
ments were made for covariates identified a priori from the
literature as being associated with either preterm birth or
dyslipidaemia, including age, race, education, income, pre-
pregnancy BMI, and smoking. Each lipoprotein subclass
was examined separately, adjusting for other lipoprotein
subclasses and triglycerides, to estimate the direct effect of
lipoproteins on preterm birth, independent of other lipids.
For example, LDL and VLDL models adjusted for total
HDL and triglyceride concentrations, whereas HDL models
adjusted for total LDL and triglyceride concentrations. We
considered lipoprotein particle concentrations measured at
<20 weeks of gestation and those measured at 24–29 weeks
of gestation separately. We also assessed the absolute
change in lipoprotein particle concentrations between the
two time points for all lipoproteins, controlling for baseline
concentrations, with the exception of medium HDLNMR.
We performed each of these analyses including all preterm
births (defined as live births <37 weeks of gestation) and
for spontaneous preterm births only.
We multiply imputed missing lipid data for those with
only one blood sample (n = 53 women) or missing covari-
ate data (n = 122) using Markov chain Monte Carlo meth-
ods (n = 50 imputations). Analyses were performed using
SAS 9.3 (SAS Institute, Cary, NC, USA).
Results
Women in our analytic  sample were predominantly 
white, married, and had greater than a high school edu-
cation. In addition, 32.2% had an income <185% of the 
poverty line, 21.0% were obese, and 10.3% smoked 
cigarettes <20 weeks of gestation. Birth outcomes 
included 100 (14.0%) preterm births and among those, 
54 (7.6%) were spontaneous preterm births. Demo-
graphic information and characteristics of the sample, 
stratified by preterm birth outcomes, are presented in 
Table 1. Preterm deliveries were more common among 
black women, women with lower education and 
incomes, as well as among women with a BMI indicative 
of underweight and overweight, compared with full-term 
deliveries.
Mean particle concentrations and average particle sizes 
stratified by preterm birth status and timing of blood draw 
are listed in Table 2. Most lipids increase over the two time 
points regardless of preterm birth status, with the exception 
of medium HDLNMR. In addition, particle size changes 
were much smaller in magnitude compared with particle 
concentration changes.
All deliveries (preterm and term)
Adjusted HRs for the association between lipoprotein 
particle concentrations and timing of delivery <37 weeks 
of gestation are shown in Table 3 (unadjusted results are 
shown in Table S1). At <20 weeks of gestation, a 1-SD 
change in large LDLNMR particle concentrations 
(HR 0.78, 95% CI 0.64–0.96), and total (HR 0.77, 
95% CI 0.61–0.98) and small (HR 0.78, 95% CI 0.62–
0.98) VLDLNMR particle concentrations, were associated 
with older gestational ages at delivery. At this same time 
point, a 1-SD change in large VLDLNMR particle concen-
trations was associated with an increased risk of earlier 
delivery (HR 1.19, 95% CI 1.01–1.41). At 24–28 weeks of 
gestation, these associations were not observed; however, 
the presence of a detectable level of medium HDLNMR 
(HR 1.90, 95% CI 1.19–3.02) and a 1-SD change in aver-
age VLDLNMR particle size (HR 1.25, 95% CI 1.03–1.51) 
were associated with an increased hazard of earlier deliv-
ery at this time point. A 1-SD change in total LDLNMR 
from <20 to 24–28 weeks of gestation was associated 
with an HR of 0.76 (95% CI 0.60–0.97), corresponding 
to older gestational ages at delivery.
The other time-varying coefficient in the Cox model 
described associations between lipoprotein particle concen-
trations and timing of term births. All 95% CIs for these 
variables included the null value of 1, indicating that lipid 
levels were unrelated to gestational age at delivery among 
term births (data not shown).
Spontaneous deliveries (preterm and term)
Adjusted HRs for the association between lipoprotein parti-
cle concentrations and timing of spontaneous preterm birth
<37 weeks of gestation are shown in Table 4 (unadjusted
results are shown in Table S2). At <20 weeks of gestation, a
1-SD change in large LDLNMR was associated with older ges-
tational ages of spontaneous delivery (HR 0.73, 95% CI
0.55–0.97). At 24–28 weeks of gestation, a 1-SD change in
total LDLNMR (HR 0.67, 95% CI 0.48–0.94) and IDLNMR
(HR 0.68, 95% CI 0.47–0.98) particle concentrations were
also associated with older gestational ages. The presence of a
detectable level of medium HDLNMR at 24–29 weeks of ges-
tation was associated with an increased risk of earlier sponta-
neous delivery (HR 1.94, 95% CI 1.01–3.75). A 1-SD change
in total LDLNMR from <20 to 24–28 weeks of gestation was
associated with a hazard ratio for spontaneous delivery of
0.59 (95% CI 0.41–0.85), and thus older gestational ages.
All 95% CIs for associations between lipoprotein particle
concentrations and timing of spontaneous delivery for term
births included the null value of 1, indicating that lipid
levels were unrelated to gestational age at delivery among
term births (data not shown).








Overall, n (%) 615 86.0 100 14.0 <0.0001 54 7.2
Gestational age (mean, SD) 39.2 1.2 33.4 3.9 <0.0001 32.9 4.3
Maternal age (mean, SD) 28.8 5.5 28 6.5 0.28 26.8 6.4
Maternal age, n (%)
≤24 years 144 23.4 28 28.0 0.06 19 35.2
25–29 years 172 28.0 32 32.0 14 25.9
30–34 years 213 34.6 21 21.0 14 25.9
35+ years 86 14.0 19 19.0 7 8.1
Maternal race & Hispanic ethnicity, n (%)
Non-Hispanic white 461 75.0 62 62.0 0.002 35 64.8
Non-Hispanic black 103 16.8 32 32.0 16 29.6
Non-Hispanic other 50 8.1 6 6.0 3 5.6
Hispanic 0 0.0 0 0.0 0 0.0
Education, n (%)
Less than high school 42 6.8 10 10.0 0.0002 5 9.3
High school graduate 77 12.5 26 26.0 18 33.3
Some college 122 19.8 24 24.0 11 20.4
College graduate 374 60.8 40 40.0 20 37.0
Income (% of poverty), n (%)
<185% 113 18.4 32 32.0 0.002 21 38.9
185–350% 142 23.1 16 16.0 5 9.3
>350% 334 54.3 42 42.0 22 40.7
Pre-pregnancy body mass index, n (%)
Underweight 26 4.2 8 8.0 0.02 6 11.1
Normal weight 342 55.6 41 41.0 23 42.6
Overweight 118 19.2 28 28.0 14 25.9
Obese 129 21.0 21 21.0 11 20.4
Prenatal cigarette smoking, n (%)* 61 9.9 13 13.0 0.15 8 14.8
Any MVPA, n (%)** 402 65.4 56 56.0 0.11 27 50.0
Nulliparous, n (%) 305 49.6 43 43.0 0.26 22 40.7
Delivered a low-birthweight infant, n (%) 9 1.5 60 60.0 <0.0001 34 63.0
Delivered an SGA infant, n (%) 33 5.4 9 9.0 0.11 1 1.9
SD, standard deviation; MVPA, moderate to vigorous physical activity; SGA, small-for-gestational age. Data were missing for the following: race
and Hispanic ethnicity (n = 1); income (n = 36); pre-pregnancy body mass index (n = 2); prenatal cigarette smoking (n = 51); MVPA (n = 3);
delivered a low-birthweight infant (n = 3); delivered an SGA infant (n = 99).
*Cigarette smoking in the first 6 months.
**MVPA at the first phone interview (17–22 weeks of gestation).
Discussion
Main findings
In this sample of pregnant women from the PIN cohort,
we used NMR to perform advanced measurements of
lipoprotein particle concentrations at two time points in
pregnancy. NMR was further able to characterise sub-
classes of these particles that were associated with gesta-
tional age at delivery. We found that particle
concentrations of VLDLNMR, LDLNMR, IDLNMR, and
HDLNMR were each independently associated with gesta-
tional age at delivery for all deliveries or for spontaneous
deliveries <37 weeks of gestation. These associations were
dynamic and dependent upon the time point in preg-
nancy at which they were assessed, such that lipoprotein
particle concentrations at <20 weeks of gestation had dif-
ferent associations with timing of delivery than those
measured at 24–28 weeks of gestation. Higher particle
concentrations of these lipoproteins at <20 weeks of gesta-
tion (small VLDLNMR, total VLDLNMR, and large
LDLNMR) were associated with older gestational ages at
delivery, but these associations were not observed at
24–28 weeks of gestation. Medium HDLNMR was associ-
ated with earlier delivery at 24–28 weeks of gestation.
Similar associations were observed with spontaneous deliv-
ery for large LDLNMR (<20 weeks of gestation) and med-
ium HDLNMR (24–28 weeks of gestation), with additional
associations observed with older gestational ages of spon-
taneous deliveries for total LDL and IDL. Medium
HDLNMR is a unique particle, as most women did not
have a detectable level. When treated as a dichotomous
variable, we found that any detectable concentration of
medium HDLNMR was associated with earlier deliveries
among all preterm and spontaneous preterm deliveries.
Strengths and limitations
This study builds on prior studies by examining the associ-
ation between lipoprotein particle concentrations and ges-
tational age at delivery using an advanced method of
lipoprotein measurement. The strengths of this study
include the large prospective cohort design, medical records
and birth outcomes readily available, and abstracted by
trained study personnel in a standardised manner, and the
collection of fasting blood samples at two time points in
Table 2. Lipoprotein particle concentrations and average particle size, by timing of blood draw; PIN study, 2001–2005 (n = 715)
Full-term deliveries All preterm deliveries
<20 weeks 24–28 weeks <20 weeks 24–28 weeks
Mean SD Mean SD Mean SD Mean SD
LDLNMR
Total 1120.05 363.97 1374.57 464.84 1154.41 456.93 1328.50 497.20
IDL 38.73 46.16 81.46 70.97 38.67 49.29 73.97 74.87
Large 669.71 239.73 845.36 304.56 598.03 237.91 793.54 313.57
Medium 82.83 81.95 87.84 97.86 106.37 101.06 98.04 108.48
Small 328.77 321.69 359.89 395.71 411.32 394.15 362.93 411.22
HDLNMR
Total 32.78 5.30 33.30 5.62 33.65 5.95 34.02 6.66
Large 11.98 3.10 12.74 2.90 11.66 3.50 12.87 3.23
Medium 0.81 1.73 0.33 1.15 1.00 2.08 0.68 1.80
Small 19.98 4.51 20.23 4.90 20.98 5.18 20.46 5.63
VLDLNMR
Total 58.91 34.31 71.91 43.20 56.28 33.23 68.01 44.43
Large 1.54 2.28 2.87 3.25 2.22 3.70 3.53 4.70
Medium 27.52 20.53 34.52 23.52 27.60 19.35 32.74 23.82
Small 29.84 18.42 34.50 24.73 26.45 19.52 31.73 25.27
Average particle size
LDLNMR 21.85 0.74 21.92 0.75 21.66 0.86 21.89 0.82
HDLNMR 9.70 0.37 9.77 0.37 9.64 0.40 9.76 0.40
VLDLNMR 49.15 8.08 51.18 8.26 50.33 7.33 53.40 10.02
Total cholesterol 203.12 35.86 244.49 46.64 198.02 37.55 235.76 49.77
Triglycerides 121.05 51.01 166.63 64.76 131.55 70.72 175.28 82.15
Concentrations were measured in particle nanomoles/l for (VLDLNMR and HDLNMR) and lmoles/l (for HDLNMR); particle size was measured in
nanometres.
pregnancy. The use of NMR to characterise lipoprotein
particle concentrations has only been reported once in a
study of pregnant women, and represents a novel way to
investigate the association between dyslipidaemia and
adverse pregnancy outcomes.
There are limitations. Some measures (e.g. pre-pregnancy
BMI, income, and smoking) were self-reported and are
subject to misclassification from recall. Confounding by
unmeasured factors may have affected the associations that
were observed. The generalisability of this study may be
limited because the women were recruited from one clinic
in North Carolina, and probably do not represent the gen-
eral population. In addition, the women in our analytic
sample were not necessarily representative of the original
pregnancy cohort because of exclusion criteria, and thus
selection bias may affect our results.
Interpretation
Previous studies have demonstrated associations between
lipid concentrations and both spontaneous and indicated
preterm birth; however, these studies did not assess lipid
particle concentrations. In studies of non-pregnant popula-
tions, lipid concentration and particle concentration are
not equivalent in their association with outcomes (i.e. car-
diovascular disease risk).19 Thus, we sought to identify
specific particles and particle concentrations that were asso-
ciated with gestational age at delivery among women in
our study.
In addition, previous studies varied in their methodol-
ogy, such as the collection of non-fasting samples, assess-
ment of different lipids, the technology used to measure
concentrations, and outcome definitions. These differences
make direct comparison with our results difficult. Prior
studies have demonstrated conflicting results. For example,
Catov et al.13 reported that mean concentrations of total
cholesterol (from non-fasting samples) at <15 weeks of ges-
tation were higher among women with preterm birth
<34 weeks of gestation, compared with those with term
births. More recently, Mudd et al.24 reported increased
odds of preterm birth among women with low total
Table 3. Adjusted hazard ratios* for the association between lipids and gestational age at delivery for births <37 weeks of gestation, PIN study,
2001–2005 (n = 715)
<20 weeks 24–28 weeks Change from <20 to
24–28 weeks
HR 95% CI HR 95% CI HR 95% CI
LDLNMR
Total 1.04 (0.85–1.27) 0.86 (0.69–1.07) 0.76 (0.60–0.97)
IDL 0.95 (0.77–1.17) 0.84 (0.66–1.06) 0.84 (0.66–1.08)
Large 0.78 (0.64–0.96) 0.82 (0.66–1.01) 0.97 (0.77–1.23)
Medium 1.21 (1.00–1.45) 1.10 (0.90–1.34) 0.95 (0.76–1.20)
Small 1.18 (0.97–1.42) 0.99 (0.81–1.22) 0.82 (0.66–1.03)
HDLNMR
Total 1.18 (0.96–1.44) 1.06 (0.86–1.30) 0.90 (0.71–1.15)
Large 0.97 (0.79–1.18) 0.98 (0.80–1.21) 1.01 (0.79–1.29)
Medium** 1.16 (0.77–1.74) 1.90 (1.19–3.02)
Small 1.19 (0.97–1.45) 1.00 (0.81–1.23) 0.80 (0.62–1.02)
VLDLNMR
Total 0.77 (0.61–0.98) 0.88 (0.70–1.12) 1.03 (0.81–1.30)
Large 1.19 (1.01–1.41) 1.15 (0.95–1.38) 1.05 (0.86–1.27)
Medium 0.82 (0.64–1.04) 0.87 (0.69–1.11) 0.93 (0.72–1.20)
Small 0.78 (0.62–0.98) 0.89 (0.71–1.11) 1.02 (0.82–1.28)
Average Particle Size LDLNMR 0.84 (0.69–1.02) 0.94 (0.77–1.15) 1.11 (0.88–1.40)
Average Particle Size HDLNMR 0.91 (0.75–1.11) 1.01 (0.82–1.24) 1.16 (0.92–1.47)
Average Particle Size VLDLNMR 1.14 (0.96–1.36) 1.25 (1.03–1.51) 1.23 (0.98–1.55)
Entries in bold indicate statistically significant estimates (P < 0.05).
*Adjusted for measured triglyceride concentration, measured total HDL concentration (LDL and VLDL models), measured total LDL concentration
(HDL models), maternal age, race (white as reference), number of years of education, household income expressed as percentage of the federal
poverty line, pre-pregnancy body mass index (normal weight as reference), and smoking.
**Medium HDLNMR is categorised as any or no detectable concentration; the change in medium HDLNMR from <20 to 24–28 weeks of gestation
was not assessed.
cholesterol, low HDL-C, and low LDL-C levels from non-
fasting samples at 15–27 weeks of gestation.
Similar to our observation that average VLDLNMR (24–
28 weeks of gestation) was associated with earlier gesta-
tional age at delivery, Thorp et al.22 observed an increased
odds of recurrent preterm birth (<35 weeks of gestation)
per nanometre increase in average VLDLNMR particle size
(OR 1.04, 95% CI 1.01–1.08). Our finding that medium
HDL NMR was associated with an increased risk of delivery
before 37 weeks of gestation is also similar to the observa-
tion that medium HDL NMR was associated with an
increased odds of recurrent preterm birth in the Thorp
et al. study. In contrast to the Thorp et al. study (in which
statistically signicant findings were only associated with an
increased odds of recurrent preterm birth), we found sev-
eral additional particles that were associated with a
decreased risk of delivery <37 weeks of gestation. Similar
to our study, Thorp et al. reported a median medium
HDLNMR concentration of 0.1 among preterm birth cases
and 0.0 among controls, suggesting that the majority of
women in their study did not have a detectable medium
HDLNMR concentration as well. Direct comparison of
results with the Thorp et al. study is limited by the fact
that their study design (nested case–control), study popula-
tion (patients with a history of a prior preterm birth), and
primary outcome (delivery <35 weeks) were different than
the present study. In addition, in the Thorp et al. study all
of the patients were exposed to 17-hydroxyprogesterone
supplementation, and a portion of the patients were
exposed to omega-3 fatty acid supplementation, which may
explain some differences in the results.
Conclusion
The association between maternal dyslipidaemia and
adverse pregnancy outcomes has been previously described
in other studies, but there is great variability in the associa-
tions found and the manner in which the exposures and
outcomes are defined. The mechanisms behind these asso-
ciations have not been elucidated. Advanced measurements
of lipid subclasses and lipoprotein particle concentrations
using NMR represent an opportunity to investigate these
Table 4. Adjusted hazard ratios* for the association between lipids and timing of delivery among spontaneous deliveries (<37 weeks of
gestation) only
<20 weeks 24–28 weeks Change from <20 to 9
24–28 weeks
HR 95% CI HR 95% CI HR 95% CI
LDLNMR
Total 0.93 (0.70–1.24) 0.67 (0.48–0.94) 0.59 (0.41–0.85)
IDL 0.89 (0.66–1.20) 0.68 (0.47–0.98) 0.69 (0.47–1.01)
Large 0.73 (0.55–0.97) 0.75 (0.56–1.00) 0.92 (0.67–1.27)
Medium 1.21 (0.95–1.56) 1.06 (0.80–1.40) 0.90 (0.65–1.23)
Small 1.11 (0.85–1.45) 0.86 (0.64–1.17) 0.72 (0.52–1.00)
HDLNMR
Total 1.14 (0.87–1.50) 1.14 (0.86–1.51) 1.07 (0.77–1.48)
Large 0.97 (0.74–1.27) 0.97 (0.73–1.29) 0.99 (0.70–1.39)
Medium** 1.09 (0.62–1.91) 1.94 (1.01–3.75)
Small 1.16 (0.88–1.52) 1.08 (0.82–1.43) 0.96 (0.69–1.33)
VLDLNMR
Total 0.76 (0.55–1.04) 0.95 (0.70–1.29) 1.15 (0.84–1.57)
Large 1.16 (0.93–1.46) 1.12 (0.87–1.44) 1.05 (0.80–1.36)
Medium 0.84 (0.62–1.14) 0.96 (0.71–1.30) 1.04 (0.75–1.43)
Small 0.74 (0.54–1.00) 0.91 (0.67–1.23) 1.09 (0.81–1.47)
Average Particle Size LDLNMR 0.85 (0.65–1.10) 0.99 (0.75–1.32) 1.19 (0.86–1.64)
Average Particle Size HDLNMR 0.94 (0.72–1.23) 1.03 (0.78–1.36) 1.14 (0.82–1.58)
Average Particle Size VLDLNMR 1.17 (0.93–1.47) 1.24 (0.95–1.62) 1.20 (0.87–1.67)
Entries in bold indicate statistically significant estimates (P < 0.05).
*Adjusted for measured triglyceride concentration, measured total HDL concentration (LDL and VLDL models), measured total LDL concentration
(HDL models), maternal age, race (white as reference), number of years of education, household income expressed as a percentage of the federal
poverty line, pre-pregnancy body mass index (normal weight as reference), and smoking.
**Medium HDLNMR is categorised as any or no detectable concentration; the change in medium HDLNMR from <20 to 24–28 weeks of gestation
was not assessed.
associations more closely, and may provide insight into the
mechanism. Our study confirms the association between
dyslipidaemia and preterm delivery, and expands the litera-
ture by identifying specific lipoprotein subclasses associated
with gestational age at delivery in our sample. These find-
ings may help formulate hypotheses for future studes of
the complex relationship between maternal lipoproteins
and preterm birth. Additional prospective studies using
advanced measurements of lipoproteins are necessary to
confirm these findings and may further elucidate underly-
ing mechanisms.
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